Source:http://linkedlifedata.com/resource/pubmed/id/11106818
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2000-12-12
|
| pubmed:abstractText |
In chronic myeloid leukemia, accurate determination of Ph(-) Hemopoietic stem cells (HSC) in peripheral blood (PB), bone marrow (BM) and leukapheresis products is important for the selection of patients for whom mobilization, collection, and autografting of Ph(-) HSC are envisaged. To this effect, the BCR/ABL fusion was assessed at the single cell level in 25 sets of PB and BM samples using dual-color I-FISH in immunophenotyped CD34(+) cells and RT-PCR of individual CFU-GM colonies. In 15 cases found to be 100% Ph(+), the respective BCR/ABL gene was absent in 30% of CD34(+) cells, while the respective transcripts could not be identified in 17% of CFU-GM. The mean percentage of BCR/ABL(-) CD34(+) cells and CFU-GM cells was higher (38% and 29%, respectively) in untreated patients than in treated patients (24% and 7%, respectively). In eight cases with cytogenetic response (CgR), the percentage of Ph(-) metaphases correlated with the level of BCR/ABL(-) colonies in BM and PB and with the proportion of BCR/ABL(-) CD34(+) cells in the BM. Immunophenotyping and FISH was fast, easy, always informative, and quantitative for the BCR/ABL(-) CD34(+) cells. Our results show that (a) at early diagnosis a high frequency of BCR/ABL(-) HSC circulate in the PB and that Ph(-) hematopoiesis is not completely suppressed; (b) although normal clonogenic cells decline rapidly within a few months after diagnosis, appreciable numbers of normal CD34(+) cells survive in chronic phase, especially in patients with CgR.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0165-4608
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
122
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
93-100
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11106818-Antigens, CD34,
pubmed-meshheading:11106818-Cell Count,
pubmed-meshheading:11106818-Fusion Proteins, bcr-abl,
pubmed-meshheading:11106818-Hematopoietic Stem Cells,
pubmed-meshheading:11106818-Humans,
pubmed-meshheading:11106818-Immunophenotyping,
pubmed-meshheading:11106818-In Situ Hybridization, Fluorescence,
pubmed-meshheading:11106818-Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative,
pubmed-meshheading:11106818-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:11106818-Middle Aged,
pubmed-meshheading:11106818-Philadelphia Chromosome,
pubmed-meshheading:11106818-RNA, Messenger,
pubmed-meshheading:11106818-Reverse Transcriptase Polymerase Chain Reaction
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Evaluation at single cell level of residual Philadelphia negative hemopoietic stem cells in chronic phase CML patients.
|
| pubmed:affiliation |
First Department of Medicine, University of Athens School of Medicine, Laikon General Hospital, 17 Agiou Thoma, Athens, Greece.
|
| pubmed:publicationType |
Journal Article
|